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The potential incubation period from exposure to onset
of symptoms was 7–39 days (median 18 days) in 20
patients with a defined period of exposure to Andes virus in
a high-risk area. This period was 14–32 days (median 18
days) in 11 patients with exposure for <48 hours.
H
antaviruses are RNAviruses that are harbored by spe-
cific rodent species and transmitted to humans by
inhalation of virus-contaminated rodent feces, urine, and
saliva (1). Human hantavirus syndromes include hemor-
rhagic fever with renal syndrome (HFRS) and hantavirus
cardiopulmonary syndrome (HCPS) (2). The latter is also
known as hantavirus pulmonary syndrome, but we prefer
HCPS because most deaths result from cardiogenic shock
(3,4).
Although HCPS is a serious problem in North and
Central America, more cases of HCPS and deaths from this
disease occur in South America; in Chile, 469 cases have
been reported through March 2, 2006, with a case-fatality
rate of 36% (5,6). Both Sin Nombre virus (SNV), the pri-
mary cause of HCPS in North America, and Andes virus,
the cause of HCPS in Chile and most cases in Argentina,
cause a severe form of HCPS. However, Andes virus is
unique among hantaviruses in that it can be transmitted
from person to person (7).
Human contact with Oligoryzomys longicaudatus (rice
rat or colilargo), the reservoir of Andes virus, occurs in
rural areas in central and southern Chile (from 28°S to
51°S). In Chile, 70% of the patients have a history of occu-
pational or peridomestic exposure to rodents or peridomes-
tic exposure to a human with HCPS; in 20% to 35%,
exposure is limited to visiting high-risk areas for recre-
ational purposes (8).
The incubation period for HCPS caused by Andes virus
has not been reported. The incubation period for HCPS
caused by SNV has been reported to be 9–33 days (9). The
incubation period for HFRS has been estimated to be 1–6
weeks (10,11) but was reported as 11–23 days after intra-
muscular or intravenous challenge in volunteers (12).
The Study
To define the incubation period for Andes virus infec-
tion, we identified 20 patients with a well-defined period
of exposure to a high-risk area among 106 persons with
HCPS enrolled in research protocols (treatment interven-
tions, contact studies, quantitative viremia during HCPS)
or interviewed by 1 of the authors. Nineteen of 20 were
residents of Santiago or other urban areas who traveled to
a high-risk area for recreational purposes. In each case, the
person resided in an urban area without Andes
virus–infected rodents and rodent-to-human transmission
and then traveled for a defined period to a high-risk area
where rodent-to-human transmission has occurred and
where Andes virus–infected rodents were found (13).
Nineteen patients reported a variety of risky activities,
such as entering or cleaning previously unused cabins or
houses, camping, or clearing land. The other patient (no.
11) was a biologist who was bitten on the finger by a
rodent, which he identified as O. longicaudatus that he had
trapped in a rural area.
The exposure period was defined as the number of days
from arrival to departure in a high-risk area. The maximum
incubation period was the time from arrival at the high-risk
area to the onset of symptoms, and the minimum incuba-
tion was the time from departure from the high-risk area to
onset of symptoms. The prodrome was defined as the peri-
od from the onset of fever or other constitutional symp-
toms until the onset of the cardiopulmonary phase and
hospitalization.
Confirmation of HCPS was based on the clinical syn-
drome with laboratory confirmation by >1 of the following
tests: ELISA for immunoglobulin G (IgG) and IgM anti-
body for hantavirus, a focus reduction assay for neutraliz-
ing antibody to Andes virus, and an RNA reverse
transcription (RT)-PCR for Andes virus. Laboratory con-
firmation was by IgG and IgM ELISA in 8 patients; IgG
and IgM ELISA plus Andes virus neutralizing antibody in
3 patients; IgG and IgM ELISA, Andes virus neutralizing
antibody, and RT-PCR in 7 patients; IgG and IgM ELISA
plus RT-PCR in 1 patient; and RT-PCR in 1 patient.
Patients had a  mean age of 30.5 years (range 2–68 years);
65% were male. The clinical course was characterized as
severe (respiratory failure and shock) in 14, moderate (res-
piratory failure without shock) in 1, and mild (respiratory
failure without requiring mechanical ventilation) in 5. Four
of 20 patients died.
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patients was 11–39 days, and the potential minimum incu-
bation period was 7–32 days. The median incubation peri-
od for all 20 patients was 18 days (range 7–39 days)
(Figure). Among the 11 patients (nos. 10–20) with expo-
sure <48 hours, the potential incubation period was 14–32
days (median 18 days). The incubation periods of patients
with mild cases (range 12–34 days) did not differ from
those of patients with moderate and severe cases (7–39
days).
Conclusions
Our study is the first to determine the incubation period
for Andes virus infection. It provides the most complete
evaluation of the incubation period for rodent-to-human
transmission for the New World hantaviruses, including
Andes virus and SNV. Young et al. reported 11 patients
with SNV infection with well-defined exposure to rodents
(9). However, only maximum or minimum incubation
periods could be determined for 4 patients. In the 7
patients for whom both minimum and maximum incuba-
tion periods could be calculated, the incubation period had
a range of 9 to 33 days. St Jeor reported SNV infection in
2 children hospitalized 3 weeks after they were bitten by a
mouse (14), but the time between the bite and the onset of
symptoms was not reported.
Human-to-human transmission of Andes virus infection
has been reported in Argentina (7,15) and Chile where
human-to-human transmission is strongly suggested in
household clusters of HCPS cases (M. Ferrés, pers.
comm.). In the 1996 outbreak in Argentina, both epidemi-
ologic and molecular evidence supported person-to-person
transmission (7,15). The time between disease onset in 14
cases of person-to-person transmission among 16 patients
with HCPS was 4–28 days. However, these intervals
should be interpreted with caution. They are based on the
mode of transmission considered most likely by Wells et
al. (15), but there were multiple cases in which patients
had contact with >1 potential source patient. Furthermore,
these were intervals between onset of symptoms in the pro-
posed source and in subsequent patients, and with 4 excep-
tions, were not calculations of an incubation period based
on defined periods of exposure to the proposed source
patient. The duration of exposure to source patients was
reported for only 4 case-patients, including 3 occupants of
a car in whom symptoms developed at 11, 15, and 29 days,
respectively, after a daylong car trip with an index patient
who was symptomatic. The shortest interval of 4 days was
for a patient who had close contact with another patient 10
days before symptoms developed. If this patient is consid-
ered to be a more likely source, as it was by Wells et al.,
the range would be 10–28 days.
In summary, our data for 11 patients in whom exposure
was limited to <48 hours showed a potential incubation
period of 14 to 32 days and a median of 18 days. Inclusion
of patients with exposure periods <14 days provided a
potential incubation period of 7 to 39 days. These data pro-
vide the most complete evaluation of the incubation period
for HCPS caused by Andes or SNV and are consistent with
available data for the incubation period for HFRS
(7,9–12,14,15).
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